Abeona Therapeutics Inc. (ABEO)

NASDAQ: ABEO · IEX Real-Time Price · USD
7.34
-0.02 (-0.27%)
At close: Mar 27, 2024, 4:00 PM
7.53
+0.19 (2.59%)
After-hours: Mar 27, 2024, 7:42 PM EDT
-0.27%
Market Cap 200.24M
Revenue (ttm) 3.50M
Net Income (ttm) -54.19M
Shares Out 27.36M
EPS (ttm) -2.53
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 130,966
Open 7.47
Previous Close 7.36
Day's Range 7.28 - 7.61
52-Week Range 2.65 - 9.01
Beta 1.48
Analysts Strong Buy
Price Target 29.00 (+295.1%)
Earnings Date Mar 18, 2024

About ABEO

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AI... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Sep 19, 1980
Employees 84
Stock Exchange NASDAQ
Ticker Symbol ABEO
Full Company Profile

Financial Performance

In 2023, ABEO's revenue was $3.50 million, an increase of 147.52% compared to the previous year's $1.41 million. Losses were -$54.19 million, 24.6% more than in 2022.

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for ABEO stock is "Strong Buy." The 12-month stock price forecast is $29.0, which is an increase of 295.10% from the latest price.

Price Target
$29.0
(295.10% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Abeona Therapeutics Reports Full Year 2023 Financial Results and Announces Completion of FDA Inspections

- FDA completed Pre-License Inspection of Abeona's Cleveland manufacturing facility, as well as inspection of clinical trial sites for pz-cel pivotal Phase 3 VIITAL™ study - - FDA completed Pre-Licens...

10 days ago - GlobeNewsWire

Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CLEVELAND, March 05, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awa...

22 days ago - GlobeNewsWire

Abeona Therapeutics Announces Progress Update on Pz-cel Biologics License Application (BLA)

- On track for PDUFA target action date of May 25, 2024 - CLEVELAND, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced, as part of the review process by the U.S...

7 weeks ago - GlobeNewsWire

Abeona Therapeutics Announces $50 Million Credit Facility

CLEVELAND, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that it has entered into a $50 million credit facility with the Avenue Venture Opportunities Fund, ...

2 months ago - GlobeNewsWire

Abeona Therapeutics Announces FDA Accepts and Grants Priority Review for Pz-cel Biologics License Application (BLA)

- PDUFA target action date is May 25, 2024 - - FDA does not currently plan to hold Advisory Committee meeting for pz-cel BLA - CLEVELAND, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Na...

4 months ago - GlobeNewsWire

Abeona Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Developments

Abeona's first-ever U.S. Biologics License Application (BLA) submission completed in September 2023 FDA decision on priority review and acceptance of BLA for pz-cel (prademagene zamikeracel, formerly ...

4 months ago - GlobeNewsWire

Abeona Therapeutics Submits Biologics License Application to U.S. FDA Seeking Priority Review and Approval of EB-101 for the Treatment of Patients with Recessive Dystrophic Epidermolysis Bullosa

CLEVELAND, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the Company has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administ...

6 months ago - GlobeNewsWire

Abeona Therapeutics Appoints Madhav Vasanthavada, Ph.D., M.B.A. as Chief Commercial Officer

CLEVELAND, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the appointment of Madhav Vasanthavada, Ph.D., M.B.A. to the role of Chief Commercial Officer (CCO...

7 months ago - GlobeNewsWire

Abeona Therapeutics Announces Participation in Upcoming Investor Conferences

CLEVELAND, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that members of its management team will participate in upcoming investor conferences in September...

7 months ago - GlobeNewsWire

Abeona Therapeutics Announces Positive Pre-BLA Meeting with FDA for EB-101 and Plans for BLA Submission

CLEVELAND, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the Company's intention to proceed with the submission of a Biologics License Application (BLA) to ...

7 months ago - GlobeNewsWire

Abeona Therapeutics Reports Second Quarter 2023 Financial Results

On track for Biologics License Application (BLA) submission in third quarter of 2023 Proceeds from $25 million registered direct offering in July allow initiation of pre-commercial launch activities f...

8 months ago - GlobeNewsWire

Abeona Therapeutics Announces Submission of Briefing Package for Pre-Biologics License Application (BLA) Meeting with FDA in August 2023

CLEVELAND, July 28, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that it has completed the submission of the briefing package to the U.S. Food and Drug Administrati...

8 months ago - GlobeNewsWire

Abeona Therapeutics Joins Rare Disease Company Coalition

CLEVELAND, July 19, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that it has joined the Rare Disease Company Coalition (RDCC), an alliance of life science companies...

9 months ago - GlobeNewsWire

Abeona Therapeutics Announces Closing of $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

CLEVELAND, July 07, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) announced the closing of its previously announced registered direct offering for total gross proceeds of $25 millio...

9 months ago - GlobeNewsWire

Abeona Therapeutics Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

CLEVELAND, July 03, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that it has raised $25 million at-the-market from select existing investors, primarily to fund init...

9 months ago - GlobeNewsWire

Abeona Therapeutics Announces Regulatory Update on Biologics License Application (BLA) for EB-101

CLEVELAND, June 09, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that it received feedback from the U.S. Food and Drug Administration (FDA) on June 8, 2023, in whic...

10 months ago - GlobeNewsWire

Abeona Therapeutics to Present at the Jefferies Healthcare Conference

CLEVELAND, June 01, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Vish Seshadri, Chief Executive Officer, will participate in a fireside chat at the Jefferies H...

10 months ago - GlobeNewsWire

Abeona Therapeutics Announces Date Change for First Quarter 2023 Portfolio Update Conference Call to May 24, 2023

CLEVELAND, May 22, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has changed the date of its previously announced First Quarter 2023 Portfolio Update conference c...

11 months ago - GlobeNewsWire

Abeona Therapeutics Announces New Preclinical Data from its AAV Ophthalmology Program at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

Animal proof-of-concept for AAV-based gene therapies for Stargardt disease, X-linked retinoschisis and autosomal dominant optic atrophy Animal proof-of-concept for AAV-based gene therapies for Stargar...

11 months ago - GlobeNewsWire

Abeona Therapeutics Reports First Quarter 2023 Financial Results

Continues to make progress toward Biologics License Application (BLA) submission for EB-101 in late-2Q/early-3Q 2023; submitted request for pre-BLA meeting

11 months ago - GlobeNewsWire

Abeona Therapeutics Announces Additional Phase 3 VIITAL™ Study Results for EB-101 Presented at the International Societies for Investigative Dermatology 2023 Meeting

CLEVELAND, May 11, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced an oral presentation of additional data from the Company's pivotal Phase 3 VIITAL™ study evaluating ...

11 months ago - GlobeNewsWire

Abeona Therapeutics Announces Multiple Abstracts Accepted from its AAV Ophthalmology Program at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

CLEVELAND, April 10, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the acceptance of three abstracts at the 26th Annual Meeting of the American Society of Gene & Cel...

1 year ago - GlobeNewsWire

Abeona Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update

Expects to submit BLA for EB-101 to FDA in late-2Q/early-3Q 2023 based on positive Phase 3 VIITAL™ study results announced in 4Q 2022

1 year ago - GlobeNewsWire

Abeona Therapeutics Announces New Employee Inducement Grants

NEW YORK and CLEVELAND, March 24, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new employees who joined Abeona.

1 year ago - GlobeNewsWire

Abeona Therapeutics Announces Acceptance of Abstract on EB-101 Phase 3 VIITAL™ Study Results for Oral Presentation at International Societies for Investigative Dermatology (ISID) 2023 Meeting

NEW YORK and CLEVELAND, March 16, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that additional data from its pivotal Phase 3 VIITAL™ study of EB-101 for recessive d...

1 year ago - GlobeNewsWire